Show less
Why I'm selling FTSE: Lambert
Clive Lambert - FuturesTechs
Friday at 6:57 GMT
Gold looks to move higher: O'Hare
Steve O'Hare - First 4 Trading
Thursday at 7:16 GMT
Bitcoin to reach new highs? — #SaxoStrats
Kay Van-Petersen
Wednesday at 10:13 GMT
Why I’m buying AUDUSD: Coleman
Ian Coleman - First 4 Trading
Tuesday at 6:22 GMT
The week ahead in macro — #SaxoStrats
Kay Van-Petersen
19 June 2017 at 9:50 GMT
Macro Monday Wk 25: A Flight of Hawks — #SaxoStrats
19 June 2017 at 9:03 GMT
When will oil find support? — #SaxoStrats
Ole Hansen
16 June 2017 at 14:04 GMT
Video / Friday at 8:23 GMT

From the Floor: Biotech surges again — #SaxoStrats

  • Biotech shares surged again, up 9% in four sessions
  • US President Donald Trump's healthcare reform bill is affecting markets
  • London set to lose more financials to Frankfurt and Dublin
  • Fixed-income volatility is subdued
By Clemens Bomsdorf
While it seems fixed-income markets "are in summer mode already“, as Saxo’s fixed-income trader Michael Boye puts it, stocks have been more volatile. 

Shares of biotech companies rallied strongly recently and are now up 9% in the last four sessions. "We have broken above key resistance levels in biotech,“ says Peter Garnry, Saxo's head of equity strategy. 

The reason for the leap in biotech stocks is the US healthcare reform bill, which, according to a piece in the New York Times, overall "will benefit the wealthy and young adults, but hurt larger numbers of people who are old or poor." In the Senate, which has to vote for the bill, Republicans have only a slight majority, but so far four senators have said they dislike the healthcare plan. So it remains unclear whether it will pass, and changes are possible. 

Gilead Sciences remains a top pick among stocks in the sector for Garnry.

In the financial sector, Morgan Stanley said it is likely to follow Goldman Sachs in choosing Frankfurt as trading hub, while Dublin will get the fund business. Other bad news for the UK includes a comment by the EU27 leaders, which, in Garnry’s view, will make a hard Brexit more likely.

Today marks the anniversary of the Brexit referendum. Since such big news are rare these days, volatility in the bond markets is low. 

“Volatility in fixed-income markets is quite low at the moment, it seems like markets are settling into summer mode,” says Boye.

The next big trigger could be the German election, says Boye, but this will not take place before September 24. 

Signs of a stabilising oil price support bond yields. 

Today’s flash PMIs from Europe and the US will be watched, but impact is unlikely to be big.

 Biotech shares are up due to US health care reform plans. Photo: Shutterstock

Clemens Bomsdorf is a consulting editor at TradingFloor

Market Predator Market Predator
@Saxostrats team: thanks for everyday broadcasted GMCs. Respect for Ole Hansen's business trip in APAC region but personally I really miss all week commodity update coverage. Saxo is big company. There is no other person able to comment Copper, Cocoa, Oil and other stuff with significant market moves? COT articles are more fundamental activity without must for intraday trading but similar question. WCU article from Ole on Friday is important like Michael O'Neills: The Week ahead/The Week that was, so it is must for me. I appreciate TF for repetitive activities because this is part of my process. No complains in my comment, just feedback. Thanks guys have a great weekend.
Relevant articles for you


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail